The effect of i.v.[intravenous] bisphosphonate [pamidronic acid] on health-related quality of life (QOL) and skeletal morbidity for newly diagnosed treatment demanding multiple myeloma. A prospective randomised double blinded dose-effective study with cost-utility analysis
Phase of Trial: Phase III
Latest Information Update: 20 Sep 2010
At a glance
- Drugs Pamidronic acid (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 20 Sep 2010 Results published in the Lancet Oncology.
- 09 May 2007 New trial record.